Market reaction was positive for Immutep, with the Australian biotech announcing progress for its lead candidate, a novel LAG-3 related immunotherapy treatment for cancer and autoimmune disease, with its shares rising 2.6% to A$0.58. 1 November 2021
Following the announcement that its Phase III TRYbeCA-1 clinical trials of eryaspase in 512 second-line patients with metastatic pancreatic cancer failed to meet its primary endpoint, shares of Lyon, France-based biotech firm Erytech Pharma plummeted as much as 40%. 28 October 2021
Now three years since its founding, US biotech Mammoth Biosciences, which is building the next generation of CRISPR products to cure and detect disease, has signed its first major R&D deal. 26 October 2021
US a multi-asset longevity biotech Cambrian Biopharma today announced the closing of an oversubscribed Series C financing, which raised $100 million. 26 October 2021
Austrian drug developer Marinomed Biotech has entered a new collaboration and licensing agreement with Chinese drugmaker Luoxin Pharmaceutical Group. 21 October 2021
UK and USA-based clinical stage biotech F-star Therapeutics today announced a license and collaboration agreement with Janssen Biotech, a subsidiary of US healthcare giant of Johnson & Johnson. 20 October 2021
Drug price disruptor EQRx has signed a memorandum of understanding (MoU) with the UK’s National Health Service, outlining plans for a long-term partnership to supply medicines. 20 October 2021
German family-owned pharma major Boehringer Ingelheim today said it has exercised its option to license UK-based Oxford Biomedica’s lentiviral vector technology to manufacture, register and commercialize BI 3720931, a lentiviral vector-based gene therapy for the treatment of cystic fibrosis (CF). 19 October 2021
Californian precision oncology company Calithera Biosciences has padded its pipeline with two assets from Japanese giant Takeda Pharmaceutical. 19 October 2021
Shares of USA-based antibacterial products developer Entasis Therapeutics were up 27% at $3.95 pre-market, as the company announced positive top-line results from its ATTACK trial - a global Phase III registrational trial evaluating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with infections caused by Acinetobacter baumannii. 19 October 2021
Physics-based US software specialist Schrödinger and Centessa Pharmaceuticals, together with the latter’s subsidiary Orexia Therapeutics, today announced an exclusive collaboration focused on the discovery of novel therapeutics targeting the orexin-2 receptor (OX2R). 18 October 2021
Shares of UK-based Silence Therapeutics were up as much as 6.5% at 556.50 pence this morning, after it revealed the signing of a potential $1.3 billion accord. 15 October 2021
Dutch antibody-drug conjugate (ADC) specialist Synaffix today presented new data regarding its topoisomerase 1 inhibitor linker-payload based on exatecan (SYNtecan E), at the World ADC Conference, showing excellent in vivo efficacy and tolerability. 13 October 2021
CNS disease specialist Supernus Pharmaceuticals and fellow USA-based Adamas Pharmaceuticals have entered a definitive agreement for Supernus to acquire Adamas, whose share shot up 75% to $8.07 by close of trading on Monday. 12 October 2021
Ensoma, a Boston, USA-based gene therapy company advancing the future of medicine through precision in vivo engineering of blood and immune cells, today announced the appointment of Emile Nuwaysir as president, chief executive officer and member of the company’s board of directors. 11 October 2021
Germany-based biotech atai Life Sciences today announced the launch of PsyProtix, a new platform company formed with Chymia, a Duke University biotechnology spinout. 11 October 2021
Following an evenly split vote from the US regulator’s advisory committee in May this year, there was good news for US biotech ChemoCentryx on Friday, as the US Food and Drug Administration approved the firm’s Tavneos (avacopan), an orally administered selective complement 5a receptor inhibitor, propelling its shares 69% higher to $33.13. 9 October 2021
Cambridge, Massachusetts, USA-based biotech Pyxis Oncology made its public debut on Friday after announcing an upside initial public offering IPO), raising $168 million at $16 a share. 9 October 2021
Fortress Biotech subsidiary Cyprium Therapeutics, with support from its licensing partner Sentynl Therapeutics, which is wholly-owned by India’s Cadila Healthcare, today announced positive results from an efficacy and safety analysis of data integrated from two completed pivotal studies in patients with Menkes disease treated with CUTX-101, copper histidinate (CuHis). 8 October 2021
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024